Dare Bioscience Files 8-K: Regulation FD Disclosure & Exhibits

Ticker: DARE · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1401914

Complexity: simple

Sentiment: neutral

Topics: compliance, regulatory-filing, corporate-governance

TL;DR

**DARE filed a routine 8-K for compliance, no new material info disclosed.**

AI Summary

Dare Bioscience, Inc. filed an 8-K on January 8, 2024, indicating a Regulation FD Disclosure and the filing of Financial Statements and Exhibits. This filing, under the 1934 Act, confirms the company's common stock (DARE) is registered on the Nasdaq Capital Market. For investors, this matters because it signals routine compliance and transparency, but without specific details on the disclosure or exhibits, it doesn't immediately suggest a major change in the company's financial health or operational outlook.

Why It Matters

This filing is a standard compliance update, confirming Dare Bioscience's adherence to SEC regulations and its listing on the Nasdaq Capital Market. It provides no new material information that would directly impact stock price or investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine compliance filing and does not introduce new risks or significant changes to the company's operations or financial standing.

Analyst Insight

A smart investor would recognize this as a routine administrative filing and would not make any immediate investment decisions based solely on this 8-K. Further investigation into the specific content of the Regulation FD Disclosure and the Financial Statements and Exhibits, once available, would be necessary for any actionable insights.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Dare Bioscience, Inc.?

This 8-K filing by Dare Bioscience, Inc. serves to report a Regulation FD Disclosure and the filing of Financial Statements and Exhibits, as indicated under 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits'.

On what date was the earliest event reported in this 8-K filing?

The Date of Report (Date of earliest event reported) for this 8-K filing is January 8, 2024.

What is the trading symbol for Dare Bioscience, Inc.'s common stock and on which exchange is it registered?

The trading symbol for Dare Bioscience, Inc.'s common stock is DARE, and it is registered on the Nasdaq Capital Market.

What is the business address and phone number of Dare Bioscience, Inc. as stated in the filing?

Dare Bioscience, Inc.'s business address is 3655 Nobel Drive, Suite 260, San Diego, CA 92122, and its telephone number is (858) 926-7655.

Under which SEC Act was this current report filed?

This current report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as indicated by 'Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934'.

Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-01-08 08:00:38

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Date: January 8, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing